Veralox nudges pipeline forward with option deal

Maryland, USA-based Veralox Therapeutics has picked up an option to acquire Nudge Therapeutics, along with its portfolio of pre-clinical cGAS inhibitor compounds.

The deal, for which financial details were not disclosed, will see Veralox continue development of Nudge's assets, with the acquisition being triggered upon the achievement of future milestones.

At the core of Veralox’s pipeline is VLX-1005, a selective 12-LOX blocker designed to treat or prevent thrombosis in heparin-induced thrombocytopenia (HIT), a rare and life-threatening condition.